Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
40.65 USD   -1.36%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 2 4679 1585 7322 850--
Enterprise Value (EV)1 1 7127 9564 9922 0892 4592 487
P/E ratio -6,00x-45,1x-12,6x-4,16x-5,30x-6,94x
Yield ------
Capitalization / Revenue 23,8x33,8x16,3x7,80x6,37x5,57x
EV / Revenue 16,5x29,4x14,2x5,72x5,50x4,86x
EV / EBITDA -4,12x-25,0x-13,5x-3,72x-5,33x-5,57x
Enterprise Value (EV) / FCF -4,62x-45,2x-12,1x-3,45x-6,29x-6,89x
FCF Yield -21,6%-2,21%-8,25%-29,0%-15,9%-14,5%
Price to Book 3,78x7,30x6,32x3,00x2,17x2,28x
Nbr of stocks (in thousands) 57 77166 15668 16270 106--
Reference price (USD) 42,713884,140,740,740,7
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 104271351365447511
EBITDA1 -416-318-368-561-462-446
Operating profit (EBIT)1 -424-330-382-617-525-464
Operating Margin -409%-122%-109%-169%-117%-90,7%
Pre-Tax Profit (EBT)1 -399-185-453-677-555-466
Net income1 -403-187-454-684-553-468
Net margin -388%-68,8%-129%-187%-124%-91,5%
EPS2 -7,12-3,07-6,70-9,76-7,67-5,85
Dividend per Share2 ------
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 79,989,390,710510298,6
EBITDA1 --137-220-135--
Operating profit (EBIT)1 -137-142-225-145-148-158
Operating Margin -171%-158%-248%-138%-144%-160%
Pre-Tax Profit (EBT)1 -152-158-239-159-159-170
Net income1 -152-158-245-154-150-163
Net margin -191%-177%-270%-146%-146%-165%
EPS2 -2,19-2,26-3,50-2,02-2,13-2,23
Dividend per Share ------
Announcement Date 05/05/202207/28/202211/02/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 7551 202740760391363
Leverage (Debt / EBITDA) 1,82x3,78x2,01x1,36x0,85x0,81x
Free Cash Flow1 -370-176-412-605-391-361
ROE (Net Profit / Equities) -63,8%-20,6%-43,7%-76,5%-223%-26,2%
Shareholders' equity1 6319061 0388952481 786
ROA (Net Profit / Asset) -43,4%-12,9%-27,7%-25,4%-16,4%-15,6%
Assets1 9281 4471 6412 6933 3743 006
Book Value Per Share2 11,319,013,313,518,717,8
Cash Flow per Share2 -6,10-2,17-4,94-8,62-5,53-6,05
Capex1 24,843,973,162,337,034,3
Capex / Sales 23,9%16,2%20,8%17,1%8,27%6,71%
Announcement Date 02/13/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 2 849 794 835
Net sales (USD) 351 406 000
Number of employees 1 119
Sales / Employee (USD) 314 036
Free-Float 95,1%
Free-Float capitalization (USD) 2 709 460 791
Avg. Exchange 20 sessions (USD) 37 872 822
Average Daily Capital Traded 1,33%
EPS & Dividend